Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.

Mørk, A; Pehrson, A; Brennum, L T; Nielsen, S Møller; Zhong, H; Lassen, A B; Miller, S; Westrich, L; Boyle, N J; Sánchez, C; Fischer, C W; Liebenberg, N; Wegener, G; Bundgaard, C; Hogg, S; Bang-Andersen, B; Stensbøl, T Bryan

Mørk, A; Pehrson, A; Brennum, L T; Nielsen, S Møller; Zhong, H; Lassen, A B; Miller, S; Westrich, L; Boyle, N J; Sánchez, C; Fischer, C W; Liebenberg, N; Wegener, G; Bundgaard, C; Hogg, S; Bang-Andersen, B; Stensbøl, T Bryan.

Affiliation

Mørk A; Synaptic Transmission 1, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen-Valby, Denmark. arm@lundbeck.com

J Pharmacol Exp Ther ; 340(3): 666-75, 2012 Mar.

Article in En | MEDLINE | ID: mdl-22171087

Subject(s)

Anti-Anxiety Agents/therapeutic use; Depressive Disorder, Major/drug therapy; Piperazines/therapeutic use; Sulfides/therapeutic use; Animals; Biogenic Monoamines/analysis; Citalopram/pharmacology; Humans; Male; Ondansetron/pharmacology; Piperazines/pharmacokinetics; Piperazines/pharmacology; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B/metabolism; Receptors, Serotonin/metabolism; Reflex/drug effects; Serotonin Plasma Membrane Transport Proteins/metabolism; Sulfides/pharmacokinetics; Sulfides/pharmacology; Vocalization, Animal/drug effects; Vortioxetine

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Sulfides / Anti-Anxiety Agents / Depressive Disorder, Major Limits: Animals / Humans / Male Language: En Journal: J Pharmacol Exp Ther Year: 2012 Type: Article Affiliation country: Denmark

Fulltext

XML

PubMed Links

Search on Google